

Appointment of new Chair Lil Bianchi and retirement of Bruce Rathie

03 October 2023

Melbourne, Australia, 03 October 2023: Respiratory imaging technology company 4DMedical Limited (ASX:4DX, “4DMedical”, or the “Company”) today advises that Chair and non-executive director, Mr Bruce Rathie, is retiring and will not be standing for re-election to 4DMedical’s Board of Directors (Board). The Board thanks Mr Rathie for his significant contribution to the Company over the past four years in these roles.

The Company announces that Lil Bianchi, current non-executive director and Chair of the Company’s Audit and Risk Committee, will take the role of Chair following Mr Rathie’s retirement. Ms Bianchi has been a director of 4DMedical since December 2019 and has international board and CEO experience across many sectors including health, finance and infrastructure. Her professional background is in technology and AI.

As a result, the Company advises the withdrawal of Item 4 from the Notice of Annual General Meeting (AGM), which was lodged with the ASX on 28 September 2023. Item 4 relates to the re-election of Mr Bruce Rathie as a director of the Company.

The withdrawal of Item 4 will not affect the validity of the proxy form provided in connection with the AGM or any proxy already submitted in respect of the remaining items. The AGM is scheduled to be held on Thursday, 2 November 2023 at 10.00am (AEDT) at The Woodward Conference Centre, Level 10, Melbourne Law School, The University of Melbourne, 186 Pelham Street, Carlton, Victoria 3053.

Mr Bruce Rathie commented:

Over the past four years, I have been pleased to lead the Company through listing on the ASX and establishment in the Australian and US markets. My goal as Chair through these formative years at 4DMedical was to establish and embed governance structures required as a publicly listed company. With these structures now in place, this AGM provides an opportune moment for me to pass the baton to Lil Bianchi and for me to pursue other opportunities.

Incoming Chair, Ms Lil Bianchi, commented:

I am absolutely delighted to take on the role of Chair at this exciting moment in the Company’s journey. 4DMedical is well positioned with globally unique technology, a strong board and strong management team, and is well capitalised to execute on its commercialisation strategy.

4DMedical MD/CEO and Founder Andreas Fouras said:

I want to thank Bruce for his significant contributions to 4DX over these past 4 years. Bruce has led us through IPO and subsequent capital raises, and all the while been a steady and patient hand guiding the Board and leading the development of governance practices of the highest standard. Bruce takes with him my best wishes and those of the entire Board and senior management team at 4DMedical.

Lil Bianchi brings the right skills and rigour for 4DMedical’s next phase of development, and I look forward to working with 4DMedical’s reinvigorated Board.



–ENDS–

Authorised by the 4DMedical Board of Directors.

Contacts

Corporate

Chief Financial Officer

Simon Glover

sglover@4dmedical.com

Administration

Company Secretary

Naomi Lawrie

companysecretary@4dmedical.com

Media Enquiries

The Capital Network (TCN)

Julia Maguire

julia@thecapitalnetwork.com.au

About 4DMedical

4DMedical Limited (ASX:4DX) is a global medical technology company that has created a step change in the capacity to accurately and quickly understand the lung function of patients with respiratory diseases.

Through its flagship patented XV Technology®, 4DMedical enables physicians to understand regional airflow in the lungs and identify respiratory deficiencies earlier and with greater sensitivity as they breathe. This technology powers 4DMedical's FDA-cleared XV Lung Ventilation Analysis Software (XV LVAS®) – the first modality to dynamically quantify ventilation throughout the lungs, and its Computed Tomography-enabled counterpart software, CT LVAS™.

XV LVAS® and CT LVAS™ reports are prepared using 4DMedical's Software as a Service delivery model using existing hospital imaging equipment or the Company's revolutionary XV Scanner.

To learn more, please visit www.4dmedical.com.